What is Generation Bio?
Generation Bio Co. is a biotechnology firm dedicated to creating non-viral genetic medicines for a range of rare and common diseases. The company leverages its proprietary cell-targeted lipid nanoparticle (ctLNP) platform, a delivery system designed to target specific tissues and cell types while avoiding off-target clearance. Complementing this is their novel immune-quiet DNA (iqDNA) technology, which enables long-lasting gene expression from non-integrating episomes, overcoming previous limitations of DNA-based therapies. Generation Bio's pipeline focuses on sickle cell disease, beta-thalassemia, and hemophilia A, with potential applications extending to other tissues such as the retina, skeletal muscle, and central nervous system. Formerly known as Torus Therapeutics, Inc., the company rebranded to Generation Bio Co. in November 2017 and is headquartered in Cambridge, Massachusetts.
How much funding has Generation Bio raised?
Generation Bio has raised a total of $235M across 3 funding rounds:
Series A
$25M
Series B
$100M
Series C
$110M
Series A (2016): $25M, investors not publicly disclosed
Series B (2018): $100M, investors not publicly disclosed
Series C (2020): $110M supported by Foresite Capital, Fidelity, Invus, Farallon, Wellington Management Company, Casdin, Deerfield, Atlas Venture, and T. Rowe Price
Key Investors in Generation Bio
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data. The firm targets breakthrough opportunities at the intersection of technology and biotechnology, employing a data science-driven investment approach.
Fidelity
Fidelity Investments is a financial services company that provides a broad range of investment, wealth management, retirement planning, brokerage, and advisory solutions for individual investors, businesses, employers, and institutions.
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.
What's next for Generation Bio?
With a major enterprise-level funding context and a recent strategic investment, Generation Bio appears to be in a scaling phase, poised to advance its therapeutic candidates through clinical development. The substantial capital infusion will likely accelerate the optimization of its ctLNP platform and iqDNA technology, enabling the company to expand its portfolio and pursue regulatory milestones. Future strategic moves may involve further partnerships or collaborations to broaden the reach of its genetic medicine treatments and solidify its market position in the competitive biotech landscape.
See full Generation Bio company page
